

## PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

## **Tagrisso**

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	00.10.100.10
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	275
Primary Phone:	Specialty/facility name	e (if applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information following q	on for this patient that muestions and sign.	nay support approval. Please answer the
Q1. Please provide ICD code(s) for diagnosis		
Q2. What diagnosis is this drug being prescribed for?		
☐ Metastatic non-small cell lung cancer (NSCLC) ☐ Other		
Q3. If you selected "other" in question 2, please provid higher recommendation per NCCN compendia or guide		use is consistent with a category 1 or
Q4. Is prescribing physician a hematology or oncology sp	pecialist?	
☐ Yes ☐ No		
Q5. If diagnosis is non-small cell lung cancer, are tumors approved test?	EGFR T790M mutatio	n-positive as detected by a FDA
☐ Yes ☐ No		
Q6. If diagnosis is metastatic non-small cell lung cancer, inhibitor (TKI) therapy?	has disease progresse	ed on or after EGFR tyrosine kinase



## PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

# **Tagrisso**

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left** 

blank or illegible may delay the review process.		
		Prescriber Name:
Patient Name:		Supervising Physician:
Yes	□No	
Q7. Additional Cor	mments	
	Prescriber Signature	Date
		ning above, I certify that applying the standard review timeframe may e or the enrollee's ability to regain maximum function
		dical necessity denial. Requesting providers may speak to a SWHP pharmacist to have an opportunity to help impact the decision on a request before coverage
entity named above. The aut	thorized recipient of this information is prohib	the sender that is legally privileged. This information is intended only for the use of the individual or ited from disclosing this information to any other party. If you are not the intended recipient, you are preference to the contents of this document is strictly prohibited. If you have received this telecopy in

error, please notify the sender immediately to arrange for the return of this document  $% \left( 1\right) =\left( 1\right) \left( 1\right) \left$